Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

NCT03870334
View directory record Official record
Conditions
Crohn's Disease
Interventions
BT-11 880 mg, Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

NCT06262607
View directory record Official record
Conditions
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Interventions
CLE-400, Vehicle
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
13
States / cities
Bryant, Arkansas • Fremont, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial

NCT01726036
View directory record Official record
Conditions
Circumcision, Male
Interventions
Gomco Circumcision Clamp, Mogen Circumcision Clamp
Device
Lead sponsor
TriHealth Inc.
Other
Eligibility
Up to 4 Days · Male only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 23, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

NCT07589634
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ramantamig, Tocilizumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 4:12 PM EDT
Withdrawn Phase 1 Interventional

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

NCT01365338
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, PF-04958242
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Randomized Therapy In Status Epilepticus

NCT04391569
View directory record Official record
Conditions
Status Epilepticus
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01486849
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo, Riluzole 50 MG
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Fresno, California • La Jolla, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 23, 2026, 4:12 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

NCT00560183
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Placebo
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

NCT01444430
View directory record Official record
Conditions
Asthma
Interventions
Symbicort pMDI, budesonide pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
160
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 23, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

The Synchrony Study: Examining Music Training for Children With FASD

NCT06005181
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
Music listening, Piano training
Behavioral
Lead sponsor
The Mind Research Network
Other
Eligibility
8 Years to 16 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness.

NCT03619265
View directory record Official record
Conditions
Range of Motion
Interventions
Prickly pear juice, Pear-flavored juice
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
35 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

NCT00326144
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 23, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413
View directory record Official record
Conditions
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions
RO7204239, RO7204239 Matching Placebo, Tirzepatide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 4:12 PM EDT
Not listed Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

NCT02149160
View directory record Official record
Conditions
Granulin Mutation
Interventions
FRM-0334, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Results available

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

NCT05873062
View directory record Official record
Conditions
Myoclonus Epilepsies, Progressive
Interventions
AUT00201, Placebo
Drug
Lead sponsor
Autifony Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 23, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227
View directory record Official record
Conditions
Fatigue, Chemotherapy Side Effects
Interventions
Armodafinil 150 mg/day, Placebo,
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 23, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

NCT01285310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Apremilast 30 mg, Apremilast 20 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 23, 2026, 4:12 PM EDT